Why did you choose to bypass the Indian market for your first GLP-1 drug launch?
Replied byKiran Mazumdar-Shaw
Founder & Executive Chairperson at Biocon
Niche: Health & Wellness
Revenue: Approx. $172 Million/month
Location: Bengaluru, Karnataka, India
Started: 1978
We launched liraglutide in the United States, Europe, and the United Kingdom. In India, the market for semaglutide was highly saturated, with forty-two companies launching products on day one. We decided to bypass that price war and focus on markets that offer better value.
0
From the Full Interview
This answer is part of a full interview with Kiran Mazumdar-Shaw, Founder & Executive Chairperson at Biocon.
Share this Answer
Found this insight valuable? Share it with your network to help others learn from Kiran Mazumdar-Shaw's experience.
Cite This Answer
Use this answer in your research, article, or academic work
Related Answers
How did you feel when you generated thousands of pounds in ten minutes from your first PDF launch?
By Krissy Cela
Health & Wellness
Approx. 16.6 Million USD/mo
Why did you choose to focus on industrial enzymes as your first business venture?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
Why did you choose your niece Claire as your successor at Biocon?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
What was it like selling your first workout PDF on a university laptop?
By Krissy Cela
Health & Wellness
Approx. 16.6 Million USD/mo
How did your challenging childhood as an Albanian immigrant in the United Kingdom shape your drive to win?
By Krissy Cela
Health & Wellness
Approx. 16.6 Million USD/mo
Why do you reject the idea that your employees are your family?
By Krissy Cela
Health & Wellness
Approx. 16.6 Million USD/mo
How did your father's liberal worldviews shape your early career decisions?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo